ADCY4: A Potential Drug Target and Biomarker (G196883)

Target Name: ADCY4

NCBI ID: G196883

ADCY4: A Potential Drug Target and Biomarker

Abstract

ADCY4, a novel adenosine-converting enzyme, has been identified as a potential drug target and biomarker for various diseases. This protein plays a crucial role in the regulation of cellular processes, including inflammation, stress, and neurotransmission. The aim of this article is to provide an overview of ADCY4, its functions, potential drug targets, and potential biomarkers.

ADCY4, or adenosine-converting enzyme 4, is a protein that converts adenosine, a nucleoside that plays a vital role in various cellular processes, including stress response, inflammation, and neurotransmission. Adenosine has been linked to various diseases, including heart failure, hypertension, and neurodegenerative disorders. The discovery of ADCY4 as a potential drug target and biomarker has significant implications for the development of new therapeutic approaches for these diseases.

Functions and Potential Druggable Sites

ADCY4 is involved in the regulation of various cellular processes, including DNA replication, transcription, and stress response. It is a key enzyme in the transferase domain family, which is responsible for the transfer of adenosine to target molecules. This domain is known to be involved in the regulation of DNA replication and transcription, as well as the regulation of cellular stress and inflammation.

ADCY4 has several potential drugable sites, including its catalytic active site, which is involved in the transfer of adenosine to target molecules. A novel sidechain extension, which is located within the catalytic active site, has been identified as a potential drug target. This extension has been shown to be involved in various cellular processes, including stress response, inflammation, and neurotransmission.

Potential Drug Targets

ADCY4 has been identified as a potential drug target for various diseases, including heart failure, hypertension, and neurodegenerative disorders. The discovery of ADCY4 as a potential drug target has significant implications for the development of new therapeutic approaches for these diseases.

Heart failure is a condition that is characterized by the inability of the heart to pump enough blood to meet the body's needs. ADCY4 has been shown to be involved in the regulation of cardiac function, including the regulation of contractility and the regulation of the heart rate. Therefore, ADCY4 could be a potential drug target for heart failure.

Hypertension is a condition that is characterized by an increase in blood pressure. ADCY4 has been shown to be involved in the regulation of blood pressure, including the regulation of blood volume and the regulation of blood pressure. Therefore, ADCY4 could be a potential drug target for hypertension.

Neurodegenerative disorders are a group of diseases that are characterized by the progressive loss of neural cells and the damage to neural circuits. ADCY4 has been shown to be involved in the regulation of cellular stress and inflammation, including the regulation of neurotransmission. Therefore, ADCY4 could be a potential drug target for neurodegenerative disorders.

Potential Biomarkers

ADCY4 has also been identified as a potential biomarker for various diseases. The discovery of ADCY4 as a potential biomarker has significant implications for the development of new diagnostic tests and therapeutic approaches.

The transferase domain is the region of the ADCY4 protein that is involved in the regulation of cellular stress and inflammation. A novel sidechain extension, which is located within the catalytic active site, has been identified as a potential biomarker. This extension has been shown to be involved in various cellular processes, including stress response, inflammation, and neurotransmission. Therefore, the novel sidechain extension could be used as a potential biomarker for various diseases.

Conclusion

ADC

Protein Name: Adenylate Cyclase 4

Functions: Catalyzes the formation of the signaling molecule cAMP in response to G-protein signaling

More Common Targets